Otivio extends exploratory MS clinical trial with FlowOx

EXECUTIVE SUMMARY

“Norwegian healthtech company, Otivio has announced that it has extended an exploratory clinical trial with Neuro-SysMed to confirm the potential of its non-invasive FlowOx medical device to alleviate multiple sclerosis symptoms.”

Screenshot from Hospital Hub April 2022

The trial follows a recent case series conducted by neurologist Dr Gabriela Fortes where FlowOx significantly alleviated MS related spasticity and pain. Due to the interesting observations, Otivio has taken the next step in extending the study to reach a total number of 15 pwMS in the exploratory trial and aim to report results and their conclusion before the summer of 2022.

You can read the article in full here!

If you would like to know more about our progress or our product, please contact us at projectmyelin@flowox.com 

Scroll to Top